EMDA-2

EMDA-2
Clinical data
Other names2-Ethoxy-4,5-methylenedioxyamphetamine; 6-Ethoxy-MDA; 6-EtO-MDA; 6-Ethoxy-MMDA-2; 6-EtO-MMDA-2
Routes of
administration		Oral
Drug classSerotonergic psychedelic; Hallucinogen
ATC code
  • None
Identifiers
  • 1-(6-ethoxy-1,3-benzodioxol-5-yl)propan-2-amine
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC12H17NO3
Molar mass223.272 g·mol−1
3D model (JSmol)
  • CCOC1=CC2=C(C=C1CC(C)N)OCO2
  • InChI=1S/C12H17NO3/c1-3-14-10-6-12-11(15-7-16-12)5-9(10)4-8(2)13/h5-6,8H,3-4,7,13H2,1-2H3
  • Key:OHOFHHFTTSOJCK-UHFFFAOYSA-N

EMDA-2, also known as 2-ethoxy-4,5-methylenedioxyamphetamine, 6-ethoxy-MDA, or 6-ethoxy-MMDA-2, is a psychedelic drug of the phenethylamine and methylenedioxyamphetamine families. It is the analogue of MMDA-2 in which the 2-methoxy group has been replaced with a 2-ethoxy group. This has resulted in EMDA-2 being described as the "TWEETIO" analogue of MMDA-2.

Use and effects

EMDA-2's dose is approximately 135 to 185 mg and its duration is about 10 to 12 hours. At 135 mg, it produced closed eye visuals, including intense colors, with sleep disturbances and a duration of some 10 hours. At 185 mg, its effects were stronger, including "marvelous" closed-eye visuals with "incredible" colors, good concentration, and distinct body tingles and rushes, with insomnia and a duration of about 12 hours. The potency of EMDA-2 is about one-third that of MMDA-2.

Interactions

History

EMDA-2 appears to have first been described in the scientific literature by at least 1975. Its effects in humans were described by Alexander Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).

Society and culture

Canada

EMDA-2 may be a controlled substance in Canada under phenethylamine blanket-ban language.

See also